HC Wainwright & Co. Reiterates Buy on Adaptimmune Therapeutics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ:ADAP) and maintained a $4 price target.
August 05, 2024 | 9:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating on Adaptimmune Therapeutics and maintained a $4 price target.
The reiteration of a Buy rating and the maintenance of a $4 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100